Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies.

Kepp O, Marabelle A, Zitvogel L, Kroemer G.

Nat Rev Clin Oncol. 2019 Oct 8. doi: 10.1038/s41571-019-0272-7. [Epub ahead of print] Review.

PMID:
31595049
2.

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.

Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smyth MJ, Soria JC, Kroemer G, Bronte V, Wargo J, Zitvogel L.

Cell Res. 2019 Oct;29(10):846-861. doi: 10.1038/s41422-019-0224-x. Epub 2019 Sep 3.

PMID:
31481761
3.

Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase 1 trials?

Simmet V, Eberst L, Marabelle A, Cassier PA.

Ann Oncol. 2019 Aug 21. pii: mdz286. doi: 10.1093/annonc/mdz286. [Epub ahead of print]

PMID:
31435659
4.

Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy.

Mekki A, Dercle L, Lichtenstein P, Nasser G, Marabelle A, Champiat S, Chouzenoux E, Balleyguier C, Ammari S.

Eur J Cancer. 2019 Sep;119:44-56. doi: 10.1016/j.ejca.2019.06.020. Epub 2019 Aug 12.

PMID:
31415986
5.

Pattern recognition receptors: immune targets to enhance cancer immunotherapy.

Shekarian T, Valsesia-Wittmann S, Brody J, C Michallet M, Depil S, Caux C, Marabelle A.

Ann Oncol. 2019 Aug 13. pii: mdz225. doi: 10.1093/annonc/mdz225. [Epub ahead of print] No abstract available.

PMID:
31408086
6.

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.

Seban RD, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S, Moya-Plana A, Mokrane FZ, Gartrell RD, Finkel G, Barker L, Bigorgne AE, Schwartz LH, Saenger Y, Robert C, Dercle L.

Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2298-2310. doi: 10.1007/s00259-019-04411-7. Epub 2019 Jul 25.

PMID:
31346755
7.

Hyperprogression during immunotherapy: do we really want to know?

Champiat S, Besse B, Marabelle A.

Ann Oncol. 2019 Jul 1;30(7):1028-1031. doi: 10.1093/annonc/mdz184. No abstract available.

PMID:
31173063
8.

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.

Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, Hollebecque A, Champiat S, Marabelle A, Massard C, Lambotte O.

JAMA Oncol. 2019 Jun 6. doi: 10.1001/jamaoncol.2019.1022. [Epub ahead of print]

PMID:
31169866
9.

Targeting CD137 enhances the efficacy of cetuximab.

Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R.

J Clin Invest. 2019 Jun 3;129(6):2595. doi: 10.1172/JCI129689. Epub 2019 Jun 3. No abstract available.

10.

Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection.

Aleynick M, Svensson-Arvelund J, Flowers CR, Marabelle A, Brody JD.

Clin Cancer Res. 2019 May 23. doi: 10.1158/1078-0432.CCR-18-1800. [Epub ahead of print] Review.

PMID:
31123052
11.

T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.

Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, Marabelle A, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C, Delaloge S, McGranahan N, André F, Zitvogel L.

Ann Oncol. 2019 Mar 29. pii: mdz112. doi: 10.1093/annonc/mdz112. [Epub ahead of print]

PMID:
30924846
12.

3OApplicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials.

Varga A, Bernard-Tessier A, Auclin E, Mezquita Pérez L, Baldini C, Planchard D, Marabelle A, Hollebecque A, Besse B, Massard C.

Ann Oncol. 2019 Feb 1;30(Supplement_1). pii: mdz027.001. doi: 10.1093/annonc/mdz027.001. No abstract available.

PMID:
30810169
13.

Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy.

Bitton K, Michot JM, Barreau E, Lambotte O, Haigh O, Marabelle A, Voisin AL, Mateus C, Rémond AL, Couret C, Champiat S, Labetoulle M, Rousseau A.

Am J Ophthalmol. 2019 Jun;202:109-117. doi: 10.1016/j.ajo.2019.02.012. Epub 2019 Feb 15.

PMID:
30772350
14.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL.

Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.

PMID:
30770348
15.

Renal toxicities associated with pembrolizumab.

Izzedine H, Mathian A, Champiat S, Picard C, Mateus C, Routier E, Varga A, Malka D, Leary A, Michels J, Michot JM, Marabelle A, Lambotte O, Amoura Z, Soria JC, Kaaki S, Quellard N, Goujon JM, Brocheriou I.

Clin Kidney J. 2019 Feb;12(1):81-88. doi: 10.1093/ckj/sfy100. Epub 2018 Nov 9.

16.

Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer.

Rouanne M, Betari R, Radulescu C, Goubar A, Signolle N, Neuzillet Y, Allory Y, Marabelle A, Adam J, Lebret T.

Eur J Cancer. 2019 Feb;108:111-119. doi: 10.1016/j.ejca.2018.12.010. Epub 2019 Jan 14.

PMID:
30654296
17.

Immunothérapie des glioblastomes.

Baldini C, Romano PM, Varga A, Champiat S, Dumont S, Dhermain F, Louvel G, Marabelle A, Postel-Vinay S, Angevin E, Gazzah A, Ribrag V, Bahleda R, Michot JM, Hollebecque A, Soria JC, Massard C.

Bull Cancer. 2018 Dec;105 Suppl 1:S59-S67. doi: 10.1016/S0007-4551(18)30391-6. Review. French.

PMID:
30595200
18.

Autres immunothérapies.

Simonaggio A, Marabelle A.

Bull Cancer. 2018 Dec;105 Suppl 1:S121-S131. doi: 10.1016/S0007-4551(18)30397-7. Review. French.

PMID:
30595193
19.

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.

Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, Lamb A, Hénon C, Dorvault N, Rouanne M, Marlow R, Bajrami I, Cardeñosa ML, Konde A, Besse B, Ashworth A, Pettitt SJ, Haider S, Marabelle A, Tutt AN, Soria JC, Lord CJ, Postel-Vinay S.

J Clin Invest. 2019 Mar 1;129(3):1211-1228. doi: 10.1172/JCI123319. Epub 2019 Feb 11.

20.

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.

Lancet Haematol. 2019 Jan;6(1):e48-e57. doi: 10.1016/S2352-3026(18)30175-3. Epub 2018 Dec 4.

PMID:
30528137
21.

Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?"

De Martin E, Michot JM, Papouin B, Champiat S, Lambotte O, Robert C, Marabelle A, Guettier C, Samuel D.

J Hepatol. 2019 Mar;70(3):566-567. doi: 10.1016/j.jhep.2018.11.016. Epub 2018 Dec 5. No abstract available.

PMID:
30527952
22.

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Letter.

Ferrara R, Susini S, Marabelle A.

Clin Cancer Res. 2019 Jun 1;25(11):3468. doi: 10.1158/1078-0432.CCR-18-3740. Epub 2018 Dec 4. No abstract available.

PMID:
30514779
23.

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.

Hirsch L, Zitvogel L, Eggermont A, Marabelle A.

Br J Cancer. 2019 Jan;120(1):3-5. doi: 10.1038/s41416-018-0294-4. Epub 2018 Nov 9.

PMID:
30413824
24.

Hyperprogressive disease: recognizing a novel pattern to improve patient management.

Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria JC, Ferté C.

Nat Rev Clin Oncol. 2018 Dec;15(12):748-762. doi: 10.1038/s41571-018-0111-2. Review.

PMID:
30361681
25.

How do immune checkpoint-targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies.

Ascierto PA, Marabelle A.

Ann Oncol. 2018 Nov 1;29(11):2157-2160. doi: 10.1093/annonc/mdy420. No abstract available.

PMID:
30307539
26.

Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation.

Gauci ML, Lanoy E, Champiat S, Caramella C, Ammari S, Aspeslagh S, Varga A, Baldini C, Bahleda R, Gazzah A, Michot JM, Postel-Vinay S, Angevin E, Ribrag V, Hollebecque A, Soria JC, Robert C, Massard C, Marabelle A.

Clin Cancer Res. 2019 Feb 1;25(3):946-956. doi: 10.1158/1078-0432.CCR-18-0793. Epub 2018 Oct 8.

PMID:
30297458
27.

Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study".

De Martin E, Michot JM, Papouin B, Champiat S, Lambotte O, Robert C, Marabelle A, Guettier C, Samuel D.

J Hepatol. 2018 Dec;69(6):1397-1398. doi: 10.1016/j.jhep.2018.09.006. Epub 2018 Oct 5. No abstract available.

PMID:
30297274
28.

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).

Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, Rahimian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhrling K, Massacesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J.

Ann Oncol. 2018 Nov 1;29(11):2163-2174. doi: 10.1093/annonc/mdy423.

29.

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.

Tran B, Carvajal RD, Marabelle A, Patel SP, LoRusso PM, Rasmussen E, Juan G, Upreti VV, Beers C, Ngarmchamnanrith G, Schöffski P.

J Immunother Cancer. 2018 Sep 25;6(1):93. doi: 10.1186/s40425-018-0407-x.

30.

Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.

Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies.

Ann Oncol. 2018 Nov 1;29(11):2175-2182. doi: 10.1093/annonc/mdy398.

PMID:
30202892
31.

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C.

Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14.

PMID:
30120041
32.

Reply to: "Mortality due to immunotherapy related hepatitis".

De Martin E, Michot JM, Papouin B, Champiat S, Lambotte O, Robert C, Marabelle A, Guettier C, Samuel D.

J Hepatol. 2018 Oct;69(4):978-979. doi: 10.1016/j.jhep.2018.07.009. Epub 2018 Aug 7. No abstract available.

PMID:
30097327
33.

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.

Bernard-Tessier A, Baldini C, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2018 Sep;101:160-164. doi: 10.1016/j.ejca.2018.06.005. Epub 2018 Jul 30.

PMID:
30071444
34.

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience.

Besle S, Schultz E, Hollebecque A, Varga A, Baldini C, Martin P, Postel-Vinay S, Bahleda R, Gazzah A, Michot JM, Marabelle A, Angevin E, Armand JP, Ribrag V, Soria JC, Massard C.

Eur J Cancer. 2018 Jul;98:17-22. doi: 10.1016/j.ejca.2018.04.019. Epub 2018 May 30.

PMID:
29859337
35.

Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1.

Michot JM, Fusellier M, Champiat S, Velter C, Baldini C, Voisin AL, Danlos FX, Dakdouki YE, Annereau M, Mariette X, Robert C, Cherif K, Marabelle A, Mateus C, Lambotte O.

Ann Rheum Dis. 2019 Jul;78(7):e67. doi: 10.1136/annrheumdis-2018-213677. Epub 2018 Jun 1. No abstract available.

PMID:
29858173
36.

Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?"

De Martin E, Michot JM, Champiat S, Lambotte O, Robert C, Marabelle A, Guettier C, Samuel D.

J Hepatol. 2018 Aug;69(2):550-551. doi: 10.1016/j.jhep.2018.04.019. No abstract available.

PMID:
29776713
37.

Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.

Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S.

Eur J Cancer. 2018 Jun;96:91-104. doi: 10.1016/j.ejca.2018.03.006. Epub 2018 Apr 23.

PMID:
29698933
38.

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

Herin H, Aspeslagh S, Castanon E, Dyevre V, Marabelle A, Varga A, Postel Vinay S, Michot JM, Ribrag V, Gazzah A, Bahleda R, Mir O, Massard C, Hollebecque A, Soria JC, Baldini C.

Eur J Cancer. 2018 May;95:68-74. doi: 10.1016/j.ejca.2018.03.002. Epub 2018 Apr 7.

PMID:
29635146
39.

Remitting Seronegative Symmetric Synovitis With Pitting Edema Associated With Partial Melanoma Response Under Anti-CTLA-4 and Anti-Programmed Death 1 Combination Treatment.

Amini-Adle M, Piperno M, Tordo J, Thomas L, Dalle S, Dubois V, Marabelle A.

Arthritis Rheumatol. 2018 Aug;70(8):1358. doi: 10.1002/art.40506. Epub 2018 Jul 7. No abstract available.

40.

Immuno-Oncology in Cancer Care is a Fantastic Opportunity for Interventional Oncology: IO4IO (Interventional Oncology for Immuno-Oncology) Initiative.

de Baère T, Tselikas L, Deschamps F, Soria JC, Marabelle A.

Cardiovasc Intervent Radiol. 2018 Jun;41(6):825-827. doi: 10.1007/s00270-018-1935-y. No abstract available.

PMID:
29549416
41.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.

42.

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.

De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D.

J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8.

PMID:
29427729
43.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.

Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.

PMID:
29413684
44.

Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.

Dercle L, Ammari S, Seban RD, Schwartz LH, Houot R, Labaied N, Mokrane FZ, Lazarovici J, Danu A, Marabelle A, Ribrag V, Michot JM.

Eur J Cancer. 2018 Mar;91:136-144. doi: 10.1016/j.ejca.2017.12.015.

PMID:
29360605
45.

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.

Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10.

PMID:
29331748
46.

Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.

Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, Champiat S, Voisin AL, Lambotte O.

Clin Microbiol Infect. 2018 Mar;24(3):216-218. doi: 10.1016/j.cmi.2017.12.003. Epub 2017 Dec 18. No abstract available.

47.

Intratumoral immunotherapy: using the tumor as the remedy.

Marabelle A, Tselikas L, de Baere T, Houot R.

Ann Oncol. 2017 Dec 1;28(suppl_12):xii33-xii43. doi: 10.1093/annonc/mdx683. Review.

PMID:
29253115
48.

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.

Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, Balleyguier C, Planchard D, Gazzah A, Soria JC, Marabelle A, Besse B, Caramella C.

Eur J Cancer. 2018 Jan;88:38-47. doi: 10.1016/j.ejca.2017.10.017. Epub 2017 Nov 26.

PMID:
29182990
49.

Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis.

Manson G, Marabelle A, Houot R.

JAMA Dermatol. 2018 Jan 1;154(1):113. doi: 10.1001/jamadermatol.2017.4421. No abstract available.

50.

The oncolytic compound LTX-401 targets the Golgi apparatus.

Zhou H, Sauvat A, Gomes-da-Silva LC, Durand S, Forveille S, Iribarren K, Yamazaki T, Souquere S, Bezu L, Müller K, Leduc M, Liu P, Zhao L, Marabelle A, Zitvogel L, Rekdal Ø, Kepp O, Kroemer G.

Cell Death Differ. 2018 Jan;25(1):227-228. doi: 10.1038/cdd.2017.148. Epub 2017 Nov 10.

Supplemental Content

Loading ...
Support Center